Palivizumab-resistant human respiratory syncytial virus infection in infancy

Clin Infect Dis. 2010 Jul 15;51(2):185-8. doi: 10.1086/653534.

Abstract

Palivizumab-resistant respiratory syncytial virus was isolated from an infant treated with palivizumab. A stable mutation at codon 276 led to a nearly complete resistance to palivizumab. Additional studies revealed a second mutation at codon 272. Further passage of the virus led to a complete loss of binding of palivizumab.

Publication types

  • Case Reports

MeSH terms

  • Amino Acid Substitution / genetics
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents / pharmacology*
  • DNA Mutational Analysis
  • Drug Resistance, Viral*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Mutation, Missense
  • Palivizumab
  • Respiratory Syncytial Virus Infections / virology*
  • Respiratory Syncytial Virus, Human / drug effects*
  • Respiratory Syncytial Virus, Human / isolation & purification

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab